newsfilter
← Latest News
Business Wire·

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Abiomed (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock (AMICS) p